# OnCo record t-maximum-pharmaceutical (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/t-maximum-pharmaceutical/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "t-maximum-pharmaceutical" ;
  schema:name "T-MAXIMUM Pharmaceutical"@en ;
  schema:alternateName "T-MAXIMUM Pharmaceutical Inc"@en, "T-MAXIMUM"@en ;
  schema:description "T-MAXIMUM Pharmaceutical develops ready-made CAR-T cell therapies from healthy donors for solid tumours. Its lead, MT027, targets B7-H3 and is given into the fluid around the brain in trials for recurrent glioblastoma and brain metastases."@en ;
  schema:url <https://onco.cc/companies/t-maximum-pharmaceutical/>, <https://t-maximum.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://t-maximum.com/>, <https://www.prnewswire.com/news-releases/t-maximum-pharmaceuticals-allogeneic-car-t-therapy-mt027-receives-fda-ind-clearance-to-proceed-to-phase-ii-clinical-trial-for-recurrent-glioblastoma-302647537.html>, <https://clinicaltrials.gov/study/NCT07386002>, <https://clinicaltrials.gov/study/NCT07897799> ;
  schema:addressCountry "CN" ;
  onco:cancers <https://onco.cc/cancers/glioblastoma/>, <https://onco.cc/cancers/secondary-brain-tumours/> ;
  onco:sections <https://onco.cc/fronts/cell-therapy/> ;
  onco:technologies <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/allogeneic-cell-therapy/>, <https://onco.cc/technologies/glioma-car-t/> ;
  onco:targets <https://onco.cc/targets/b7h3/>, <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/her2/> .